Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.

病毒学 不利影响 安慰剂 血清转化 临床试验 效价 随机对照试验 耐受性 佐剂 内科学 免疫系统 严重急性呼吸综合征冠状病毒2型(SARS-CoV-2) 抗体效价 中和抗体
作者
David Hillus,Tatjana Schwarz,Pinkus Tober-Lau,Kanika Vanshylla,Hana Hastor,Charlotte Thibeault,Stefanie Jentzsch,Elisa T Helbig,Lena J Lippert,Patricia Tscheak,Marie Luisa Schmidt,Johanna Riege,André Solarek,Christof von Kalle,Chantip Dang-Heine,Henning Gruell,Piotr Kopankiewicz,Norbert Suttorp,Christian Drosten,Harald Bias,Joachim Seybold,Florian Klein,Florian Kurth,Victor M. Corman,Leif E. Sander
出处
期刊:The Lancet Respiratory Medicine 卷期号:9 (11): 1255-1265 被引量:68
标识
DOI:10.1016/s2213-2600(21)00357-x
摘要

Summary Background Heterologous vaccine regimens have been widely discussed as a way to mitigate intermittent supply shortages and to improve immunogenicity and safety of COVID-19 vaccines. We aimed to assess the reactogenicity and immunogenicity of heterologous immunisations with ChAdOx1 nCov-19 (AstraZeneca, Cambridge, UK) and BNT162b2 (Pfizer-BioNtech, Mainz, Germany) compared with homologous BNT162b2 and ChAdOx1 nCov-19 immunisation. Methods This is an interim analysis of a prospective observational cohort study enrolling health-care workers in Berlin (Germany) who received either homologous ChAdOx1 nCov-19 or heterologous ChAdOx1 nCov-19–BNT162b2 vaccination with a 10–12-week vaccine interval or homologous BNT162b2 vaccination with a 3-week vaccine interval. We assessed reactogenicity after the first and second vaccination by use of electronic questionnaires on days 1, 3, 5, and 7. Immunogenicity was measured by the presence of SARS-CoV-2-specific antibodies (full spike-IgG, S1-IgG, and RBD-IgG), by an RBD–ACE2 binding inhibition assay (surrogate SARS-CoV-2 virus neutralisation test), a pseudovirus neutralisation assay against two variants of concerns (alpha [B.1.1.7] and beta [B.1.351]), and anti-S1-IgG avidity. T-cell reactivity was measured by IFN-γ release assay. Findings Between Dec 27, 2020, and June 14, 2021, 380 participants were enrolled in the study, with 174 receiving homologous BNT162b2 vaccination, 38 receiving homologous ChAdOx1 nCov-19 vaccination, and 104 receiving ChAdOx1 nCov-19–BNT162b2 vaccination. Systemic symptoms were reported by 103 (65%, 95% CI 57·1–71·8) of 159 recipients of homologous BNT162b2, 14 (39%, 24·8–55·1) of 36 recipients of homologous ChAdOx1 nCov-19, and 51 (49%, 39·6–58·5) of 104 recipients of ChAdOx1 nCov-19–BNT162b2 after the booster immunisation. Median anti-RBD IgG levels 3 weeks after boost immunisation were 5·4 signal to cutoff ratio (S/co; IQR 4·8–5·9) in recipients of homologous BNT162b2, 4·9 S/co (4·3–5·6) in recipients of homologous ChAdOx1 nCov-19, and 5·6 S/co (5·1–6·1) in recipients of ChAdOx1 nCov-19– BNT162b2. Geometric mean of 50% inhibitory dose against alpha and beta variants were highest in recipients of ChAdOx1 nCov-19–BNT162b2 (956·6, 95% CI 835·6–1095, against alpha and 417·1, 349·3–498·2, against beta) compared with those in recipients of homologous ChAdOx1 nCov-19 (212·5, 131·2–344·4, against alpha and 48·5, 28·4–82·8, against beta; both p Interpretation The heterologous ChAdOx1 nCov-19–BNT162b2 immunisation with 10–12-week interval, recommended in Germany, is well tolerated and improves immunogenicity compared with homologous ChAdOx1 nCov-19 vaccination with 10–12-week interval and BNT162b2 vaccination with 3-week interval. Heterologous prime-boost immunisation strategies for COVID-19 might be generally applicable. Funding Forschungsnetzwerk der Universitatsmedizin zu COVID-19, the German Ministry of Education and Research, Zalando SE.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
秋风的应助被快乐乐巧采纳,获得10
1秒前
1秒前
2秒前
linlianhao发布了新的文献求助10
2秒前
水煮电吹风的应助被www333ccc采纳,获得10
5秒前
5秒前
帅气鲨鱼发布了新的文献求助10
5秒前
snow完成签到 ,获得积分20
5秒前
6秒前
luyiyi发布了新的文献求助10
6秒前
6秒前
11发布了新的文献求助50
7秒前
星辰大海的应助被伶俐鹤轩采纳,获得20
7秒前
igiss发布了新的文献求助10
7秒前
完美世界的应助被别梦寒采纳,获得10
8秒前
芋圆发布了新的文献求助30
8秒前
隐形曼青的应助被潇洒盼柳采纳,获得30
9秒前
海芝士莓果酱完成签到,获得积分10
9秒前
9秒前
小花花发布了新的文献求助10
9秒前
10秒前
11秒前
11秒前
11秒前
11秒前
11秒前
12秒前
12秒前
13秒前
you完成签到,获得积分10
14秒前
简单面包完成签到,获得积分10
14秒前
15秒前
跳跃发布了新的文献求助10
15秒前
小马甲的应助被GBY采纳,获得10
15秒前
风清扬发布了新的文献求助10
15秒前
初景发布了新的文献求助10
16秒前
bkagyin的应助被爱吃香菜采纳,获得10
16秒前
小羊6680发布了新的文献求助10
16秒前
17秒前
zzk完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067